GALD — Galderma AG Income Statement
0.000.00%
Last trade - 00:00- CH₣21.37bn
- CH₣23.27bn
- $4.44bn
Annual income statement for Galderma AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 3,445 | 3,824 | 4,117 | 4,440 |
| Cost of Revenue | ||||
| Gross Profit | 2,411 | 2,630 | 2,885 | 3,085 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 3,181 | 3,513 | 3,581 | 3,795 |
| Operating Profit | 264 | 311 | 536 | 645 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -79.7 | -51.9 | 11 | 310 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -84.3 | -96.9 | -57.1 | 231 |
| Net Income Before Extraordinary Items | ||||
| Extraordinary Items | ||||
| Net Income | -156 | -98.5 | -57.1 | 231 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -156 | -98.5 | -57.2 | 231 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.146 | -0.211 | -0.128 | 1.05 |
| Dividends per Share |